Presented by expert speakers, our webinars will give you advance insight into topics that will be covered at the event.
Can’t make the date? Still register to receive the webinar recording afterwards.
To Overcome the Challenges in Cancer Treatment - From Bone Metastasis to Nanotechnology
Tue, May 4, 2021 | 4:00 PM - 5:00 PM BST
Presented by Jukka Rissanen, PhD, CEO, Pharmatest Services | Sanna Käkönen, PhD, Founder, CEO, Aurexel Life Sciences Ltd, Adjunct Professor, University of Turku | Joy Wolfram, PhD, Assistant Professor, Mayo Clinic
The complexity of the cross-talk between tumor and bone microenvironment is characteristic of the metastatic bone disease occurring in various cancers, such as breast and prostate cancer and multiple myeloma. Animal models can be used to evaluate the mode-of-action and efficacy of new targeted therapies in bone metastasis.
Nanomedicine enables new opportunities for targeted drug delivery thus reducing the adverse effects of treatment on healthy cells. Use of nanotechnology has the potential to change the course of diagnostics and treatment of cancer by integrating the unique characteristics of nanoparticles combined with strategies to modify the microenvironment.
Introduction by Pharmatest Services
Jukka Rissanen, PhD, CEO, Pharmatest Services
PRESENTATION 1: Breaking the vicious crosstalk – Using preclinical models to identify compounds to combat metastatic bone disease
Sanna Käkönen, PhD, Founder, CEO, Aurexel Life Sciences Ltd.
Adjunct Professor, University of Turku
- Understanding the crucial role of bone microenvironment in tumor dormancy and growth
- Utilizing animal models of bone metastasis to elucidate the effect of new therapeutic compounds on tumor and its microenvironment
- Investigating the mode-of–action of compounds inhibiting tumor growth in bone in order to facilitate clinical development
PRESENTATION 2: Extracellular vesicles in cancer
Joy Wolfram, PhD, Assistant Professor, Mayo Clinic
- Improved methods for extracellular vesicle isolation and storage
- Extracellular vesicles as drug delivery vehicles
- Diagnostic and pathological roles of extracellular vesicles in cancer
Sanna Käkönen, PhD, Adjunct Professor Founder, CEO – While preparing her PhD thesis in Molecular Biotechnology and In Vitro Diagnostics between 1993-1999, Dr. Sanna Käkönen held various research assistant, teaching and scientist positions at the Division of Biotechnology, University of Turku. Following her two-year postdoctoral position as a Research Fellow at the University of Texas Health Science Center, she spent one year as an Assistant Professor at the same institution continuing her work on molecular mechanisms, animal models and imaging of cancer metastases. After her academic career Sanna continued her work in cancer biology and cancer drug development for over a decade in the international pharmaceutical industry, first with Schering (later Bayer) in Berlin and later with Amgen, before finally founding Aurexel Life Sciences in 2012.
Dr. Joy Wolfram leads a nanomedicine research laboratory with the goal of developing innovative nanoparticles that bring the next generation of treatments directly to the clinic. She has designed many preclinical nanoparticles for treating cancer and other life-threatening diseases and has authored over 50 publications in the past five years. She is the director of the Nanomedicine and Extracellular Vesicles Laboratory at Mayo Clinic in Jacksonville, Florida and holds affiliate faculty positions at the Houston Methodist Hospital and the University of North Florida. She is a board member and scientific advisor of several companies around the world with a cumulative customer base of over 18 million. Her mission is to inspire and support underrepresented minorities in science. She is actively involved in community outreach and scientific education, including serving as the chair of an Education and Outreach Working Group of the National Cancer Institute in the United States.